SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Keytruda Monotherapy Reduced Progression or Death Risk by 43%

The headline reports a 43% reduction for certain patients with advanced or recurrent endometrial cancer with mismatch repair-deficient tumors versus chemotherapy.

MRK

Related stories